Blood Cancer UK partners with RareCan to improve delivery of clinical trials
Charity Blood Cancer UK has teamed up with oncology company RareCan to support the organisation’s delivery of clinical trials focussed on the prevention, diagnosis, or treatment of rare cancers.
Excerpt from the Press Release:
Blood cancer
The partnership will see Blood Cancer UK join the charity network GIST Cancer UK as RareCan’s partner. The aim is to enable people living with forms of rare blood cancers, such as leukaemia, lymphoma, and myeloma, to volunteer to take part in potentially lifesaving clinical research, by providing tissue and blood samples, and genetic data.
Blood cancer is the UK’s third biggest cancer killer, with around 15,000 people dying each year. With surgery and radiotherapy rarely an option for treating this kind of cancer, it’s crucial that investment into research to find new and better treatments continues so even more lives can be saved.
RareCan offers a source of information to researchers by providing rapid, joined up access to patients, data and bio-samples, reducing the time it takes researchers to find the exact patients or tissue needed for their rare cancer targets from months to weeks.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?